“I’m thrilled to welcome Dr. Edward Evantash to our outstanding and growing team at Alydia Health,” said Anne Morrissey, Chief Executive Officer. “His extensive executive leadership experience and the impressive clinical background will prove invaluable to Alydia in our mission to make childbirth safer for all mothers. As we prepare for commercialization of the Jada System for postpartum hemorrhage (PPH) or abnormal postpartum uterine bleeding, Edward’s leadership in the obstetrical community and societies will be vital to achieving our mission.”
Dr. Evantash has dedicated his career to improving all aspects of medical care for women. In his most recent role as Medical Director and Vice President, Global Medical Affairs at Hologic, Dr. Evantash helped expand the company’s portfolio to include products that improve women’s health and well-being. Dr. Evantash previously served as Division Chief of Obstetrics and Gynecology at Tufts Medical Center while directing the medical student clerkship as an Assistant Professor. He received his medical degree from the University of Pennsylvania School of Medicine as a Penn Scholar.
“The team at Alydia is addressing a major problem in women’s health by focusing on postpartum hemorrhage or abnormal uterine bleeding, where there is an immense need for additional treatment options,” said Dr. Evantash. “Having practiced as an OB-GYN for nearly 20 years, I’ve seen firsthand the burden that childbirth complications requiring invasive treatments can have on new mothers, their families, and their health care providers. I share Alydia’s passion for bringing much-needed innovation to maternal health and look forward to helping the organization advance new technologies for postpartum hemorrhage and abnormal uterine bleeding in the U.S. and globally.”
The Jada System™ is an innovative technology designed to rapidly control and treat PPH or abnormal postpartum uterine bleeding by encouraging the uterus to contract quickly, naturally compressing the open blood vessels. Alydia recently completed enrollment in the PEARLE IDE Study to support the company’s planned 510(k) submission to the U.S. Food and Drug Administration (FDA) for marketing clearance of the Jada System.
Facts provided by the company:
Immediately following childbirth, the uterus should contract to stop the normal bleeding associated with delivery. A mother with risk factors such as a long or challenging delivery might find that her uterus is unable to contract on its own, causing uncontrolled bleeding known as postpartum hemorrhage (PPH) or abnormal postpartum uterine bleeding. PPH is one of the most common complications of birth that can result in emergency interventions such as hysterectomy, expensive blood transfusions, and, in some cases, maternal death. According to the Centers for Disease Control and Prevention (CDC), severe maternal morbidity has been steadily increasing in the U.S. in recent years, nearly tripling between 1993 and 2014.1 Despite the unacceptably high rate of complications from childbirth requiring treatment, there remains a significant need for effective therapies.